MDT vs SHC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MDT and SHC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MDT and SHC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans four main areas: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform), and Diabetes (insulin pumps and continuous glucose monitoring). The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics.

Full MDT guide

Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. Sterigenics, the largest of the three units, runs contract sterilization plants using gamma irradiation, ethylene oxide and electron beam, and has done that work for more than 90 years. Nordion supplies the cobalt-60 that makes gamma sterilization possible, along with the irradiator systems that house it, and the company estimates gamma handles roughly 30% of single-use medical device sterilization worldwide. Nelson Labs sells microbiological and analytical chemistry testing (over 900 distinct tests) plus the regulatory advisory work customers need to validate a sterilization method and defend it to a regulator. Revenue for the twelve months to June 30, 2026 was ~$1.22 billion across 62 facilities and more than 3,000 employees. The customer list is concentrated at the top of the industry: over 40 of the top 50 medical device companies and nine of the ten largest global pharmaceutical companies. More than 90% of both Sterigenics and Nordion revenue in 2025 came from customers on multi-year contracts, so volumes track device production rather than any discretionary spending cycle.

Full SHC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
• SHC drivers: Contracted volume and repeat pricing; Nordion's cobalt-60 position and the harvest cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. For SHC, the ethylene oxide tort docket is the dominant, partly quantified risk.

Pick MDT if you believe its drivers more; SHC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MDT and SHC guides.

MDT. Medtronic trades at a moderate valuation relative to faster-growing medtech peers, reflecting its scale, diversification, and reliable dividend but also a track record of slower organic growth. The multiple has expanded when new product cycles reaccelerated growth and compressed during periods of execution stumbles. The yield gives it a defensive, income-oriented profile within healthcare.

SHC. Roughly 12x enterprise value to adjusted EBITDA is a modest price for a business earning 51% EBITDA margins on largely contracted revenue from a regulated, hard-to-replicate asset base. The discount is the litigation. Sotera carries no reserve for the ~970 ethylene oxide claims still outstanding, so the multiple embeds an unpriced tail rather than a known cost. The trailing GAAP P/E of ~34x, meanwhile, reflects amortization, interest and settlement charges that the adjusted figures strip out.

Headline figures (approximate, early 2026): MDT shows revenue (ttm) ~$33 billion, operating margin ~20% (non-GAAP higher; GAAP affected by amortization), net income (ttm) ~$4.5 billion, eps (ttm) ~$3.50 GAAP; non-GAAP higher; SHC shows revenue (ttm) ~$1.22 billion for the twelve months to June 30, 2026, up ~8% from ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Second-quarter 2026 revenue was $321.4 million, up 9.2% year over year and 8.0% in constant currency. On August 6, 2026 management raised full-year guidance to $1.236 billion to $1.254 billion, implying 5.25% to 6.75% constant-currency growth plus an estimated 100 basis points of currency benefit., earnings and eps GAAP net income of ~$163.5 million for the twelve months to June 30, 2026, against $77.9 million in fiscal 2025 and $44.3 million in fiscal 2024. Trailing diluted EPS is $0.57, putting the shares near 34x reported earnings. The year-on-year comparison flatters 2026 because fiscal 2025 absorbed $64.9 million of Illinois settlement charges and heavier intangible amortization. Q2 2026 net income was $53.6 million ($0.19 diluted) versus $8.0 million ($0.03) a year earlier; adjusted EPS of $0.26 rose 30%, and full-year adjusted EPS guidance is $0.95 to $1.01., segment mix and margins For fiscal 2025, Sterigenics contributed $755.8 million of revenue (65% of the total) at a 54.6% segment margin, Nordion $187.6 million (16%) at 57.3%, and Nelson Labs $220.2 million (19%) at 33.3%. In the second quarter of 2026 those revenues were $211.6 million, $49.1 million and $60.7 million, with segment income of $118.1 million, $28.0 million and $19.6 million. Consolidated adjusted EBITDA margin was 51.6% in the quarter and 51.1% on a trailing twelve-month basis. Nelson Labs is the swing factor, having fallen 3.9% in 2025., cash flow and capital spending Net cash from operating activities was $117.9 million in the first half of 2026 versus $112.9 million a year earlier, with $88 million of it in the second quarter. Capital expenditure was $92.6 million in the half against $51.1 million in the prior-year half, and full-year 2026 guidance is $200 million to $225 million, close to 17% of revenue. Free cash flow is therefore a small fraction of the $621.6 million of trailing adjusted EBITDA, because cobalt supply, plant capacity and emissions controls all consume cash..

MDT and SHC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MDT and SHC exposure against your real portfolio. It is not an investment adviser.